152 related articles for article (PubMed ID: 38483358)
1. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review.
Motallebzadeh Khanmiri J; Alizadeh M; Esmaeili S; Gholami Z; Safarzadeh A; Khani-Eshratabadi M; Baghbanzadeh A; Alizadeh N; Baradaran B
Cytotherapy; 2024 May; 26(5):427-435. PubMed ID: 38483358
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.
van de Loosdrecht AA; van Wetering S; Santegoets SJAM; Singh SK; Eeltink CM; den Hartog Y; Koppes M; Kaspers J; Ossenkoppele GJ; Kruisbeek AM; de Gruijl TD
Cancer Immunol Immunother; 2018 Oct; 67(10):1505-1518. PubMed ID: 30039426
[TBL] [Abstract][Full Text] [Related]
4. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
5. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
Anguille S; Van de Velde AL; Smits EL; Van Tendeloo VF; Juliusson G; Cools N; Nijs G; Stein B; Lion E; Van Driessche A; Vandenbosch I; Verlinden A; Gadisseur AP; Schroyens WA; Muylle L; Vermeulen K; Maes MB; Deiteren K; Malfait R; Gostick E; Lammens M; Couttenye MM; Jorens P; Goossens H; Price DA; Ladell K; Oka Y; Fujiki F; Oji Y; Sugiyama H; Berneman ZN
Blood; 2017 Oct; 130(15):1713-1721. PubMed ID: 28830889
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination in acute myeloid leukemia.
Anguille S; Willemen Y; Lion E; Smits EL; Berneman ZN
Cytotherapy; 2012 Jul; 14(6):647-56. PubMed ID: 22686130
[TBL] [Abstract][Full Text] [Related]
8. [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].
Anguille S; Van Tendeloo V; Berneman Z
Bull Cancer; 2012 Jun; 99(6):635-42. PubMed ID: 22641288
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic cancer vaccine therapy for acute myeloid leukemia.
Wu M; Wang S; Chen JY; Zhou LJ; Guo ZW; Li YH
Immunotherapy; 2021 Jul; 13(10):863-877. PubMed ID: 33955237
[TBL] [Abstract][Full Text] [Related]
10. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
[TBL] [Abstract][Full Text] [Related]
11. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.
Subklewe M; Geiger C; Lichtenegger FS; Javorovic M; Kvalheim G; Schendel DJ; Bigalke I
Cancer Immunol Immunother; 2014 Oct; 63(10):1093-103. PubMed ID: 25186611
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intracellular immune checkpoint-silenced DC vaccine.
Wang D; Huang XF; Hong B; Song XT; Hu L; Jiang M; Zhang B; Ning H; Li Y; Xu C; Lou X; Li B; Yu Z; Hu J; Chen J; Yang F; Gao H; Ding G; Liao L; Rollins L; Jones L; Chen SY; Chen H
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415891
[TBL] [Abstract][Full Text] [Related]
13. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
16. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
17. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
[TBL] [Abstract][Full Text] [Related]
18. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
Klammer M; Roddie PH
Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
[TBL] [Abstract][Full Text] [Related]
19. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
Delluc S; Hachem P; Rusakiewicz S; Gaston A; Marchiol-Fournigault C; Tourneur L; Babchia N; Fradelizi D; Regnault A; Sang KH; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2009 Oct; 58(10):1669-77. PubMed ID: 19225777
[TBL] [Abstract][Full Text] [Related]
20. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
